Position in NVS
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$286,954
New position
Shares Held
1,831
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#1,153
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Astoria Portfolio Advisors LLC. holds $9,341,449 across 9 Drug Manufacturers - General names. NVS ranks #7 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
10,976 | $2,762,000 | |
| 2 | LLY |
ELI LILLY & Co
|
2,257 | $2,707,113 | |
| 3 | JNJ |
Johnson & Johnson
|
5,374 | $1,364,834 | |
| 4 | AMGN |
Amgen Inc
|
2,028 | $734,379 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
4,555 | $575,478 | |
| 6 | AZN |
Astrazeneca PLC
|
2,426 | $460,018 | |
| 7 | NVS |
Novartis AG
This page
|
1,831 | $286,954 | |
| 8 | MRK |
Merck & Co., Inc.
|
1,888 | $242,608 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $286,954 | 1,831 | Shares | Sole | 2026-07-28 | |
| No filing history on record for this holder in this stock. | ||||||